FAQs - Frequently Asked Questions
about Diasorin
Corporate, Governance & Investor Relations
Clear information on the company (who we are), governance, leadership, and financial reporting.
Access Diasorin’s governance structure, leadership profiles, ESG commitments, financial documentation, and resources for investors and stakeholders.
Diasorin addresses social responsibility and community engagement through both corporate initiatives and the work of Fondazione Diasorin.
Key actions include:
- Awareness and diagnosis and prevention campaigns on topics such as antimicrobial resistance and tuberculosis, developed with scientific societies and institutions;
- Long-term support for educational projects, such as the “Mad for Science” competition, which brings high-school students closer to STEM disciplines and supports school laboratories;
- Sponsorship of inclusive sports and community events that promote accessibility, such as the Giovanni Nasi Trophy and the Diasorin Cup for sitting volleyball.
Learn more about Diasorin’s social responsibility and community engagement
Diasorin’s environmental approach focuses on improving the sustainability of its operations and manufacturing processes through:
- A 2023–2025 environmental plan that includes to improve global energy efficiency and reduce greenhouse gas emissions;
- Alignment of manufacturing sites with ISO 14001 (environmental management) and ISO 45001 (health and safety) standards, to manage both environmental aspects and employee safety;
- Detailed monitoring of energy consumption and mix (fossil, nuclear, renewable) across plants, with increasing use of certified renewable energy at key sites.
Learn more about Diasorin's approach to environmental sustainability
In its official materials, Diasorin presents innovation as a central driver of growth, highlighting:
- significant R&D investments (over €130 million in 2024) in new technologies, assay development and platform optimization;
- a pipeline of new immunodiagnostic and molecular solutions, such as LIAISON® assays, LIAISON® PLEX® multiplex panels, and other specialty tests introduced or cleared during the year;
- a strategic focus on expanding its menu and platforms for key clinical areas, and on strengthening its presence in the US and other priority markets.
These elements are typically presented in the “Diasorin World”, “Research and Development”, and “Sustainability and Strategy” sections of the Annual Financial Report, as well as in investor presentations.
Diasorin publishes a wide range of governance and sustainability information, including:
- corporate governance documents (By-Laws, procedures, Code of Ethics, reports on corporate governance),
- Board of Directors composition and roles,
- sustainability reports and policies, including the consolidated sustainability statement within the Annual Financial Report.
The Governance and Sustainability sections describe how the Board of Directors and the Control, Risk and Sustainability Committee oversee impacts, risks and opportunities, including ESG topics, and how these are integrated into the Group’s business model and reporting processes.
Visit the Investors section
Visit the Sustainability section
You can access Diasorin’s investor relations resources from the Investors section of the Diasorin website.
This area includes financial results, quarterly presentations, press releases, Annual and Interim Reports, and Investor Day materials. It also provides analyst coverage and contact details for the Investor Relations team.
If you need direct contact, you can use the Keep in touch option available in the Investors section to subscribe to Investor Relations communications and press releases.
Diasorin is a global diagnostics company with a strong presence in North America, Europe and Asia, and a growing role in other regions worldwide.
The Group operates through manufacturing sites, R&D centers and commercial subsidiaries that serve clinical laboratories and healthcare providers globally.
As of 2024, Diasorin employs more than 3,200 people, with the largest portions of its workforce based in the United States and Italy, reflecting the strategic importance of these markets.
The company highlights its position as a specialty diagnostics leader and a partner for major global diagnostic players, supported by long-term collaborations and a broad installed base of diagnostic systems.
You can find Diasorin’s annual and interim reports in the Investors → Financial Corner → Annual and Interim Reports section on the Diasorin website.
This page provides PDFs of the full Annual Financial Report, half-year reports, and all related financial documentation, including consolidated financial statements and the consolidated sustainability reports.
Diasorin’s business model starts from the real needs of the healthcare world and translates them, through research and technological development, into diagnostic tools and solutions that support clinical decision-making.
The model reflects the Group’s purpose of delivering answers to unmet medical needs by combining scientific innovation, proprietary platforms, and integrated laboratory and point-of-care diagnostic processes.
Diagnostic solutions tailored to clinical workflows (e.g., laboratory testing and point-of-care diagnostics), Licensed technologies that enable partners to develop new products, Integration of research, development, and market adoption to ensure that innovations translate into real healthcare value for patients and healthcare systems worldwide.
This model helps Diasorin create long-term value by connecting scientific innovation with practical healthcare applications, while maintaining alignment with market needs and regulatory standards.
Partnerships and acquisitions play a strategic role in strengthening Diasorin’s innovation ecosystem.
The Group combines internal scientific expertise with external collaborations, technology licensing agreements, and selective acquisitions to enhance its capabilities and accelerate innovation.
These initiatives support the development of new diagnostic solutions, expand technological platforms, and reinforce Diasorin’s position as a global player in specialty diagnostics, while remaining aligned with the Group’s long-term strategic objectives.
Diasorin’s corporate information is available through dedicated sections of the corporate website, designed to provide a clear and consolidated view for different stakeholders.
Key reference areas include:
- Who we are – company profile, history, and identity;
- Governance – corporate governance framework and official documents;
- Investors – financial results, reports, and market information;
- Sustainability – ESG strategy, objectives, and reporting.
Together, these sections provide an integrated overview of Diasorin’s corporate profile and strategic direction.
The Group’s approach to innovation is driven by continuous investment in research and development, scientific expertise, and a strong focus on specialty diagnostics, where clinical value and differentiation are highest.
Diasorin’s innovation efforts are designed to support sustainable growth, strengthen proprietary platforms, and respond to evolving healthcare needs, while operating within a highly regulated and quality-driven environment.
Diasorin is a global leader in specialty diagnostics, with a strong focus on immunodiagnostics and molecular diagnostics.
Explore who we are
The Group operates with an integrated business model that combines proprietary platforms, a broad and expanding test menu, and a strong presence in key healthcare markets, particularly the United States and Europe.
Discover our story
Diasorin’s positioning is reinforced by long-term investments in innovation, selective acquisitions (such as Luminex Corporation), and strategic partnerships that strengthen its technology portfolio and global reach.
Learn more about our business model
You might find this interesting
Diagnostic Products and Technologies
Explore Diasorin’s diagnostic platforms and solutions.
Discover the immunodiagnostic and molecular diagnostic technologies that power Diasorin’s test portfolio and support clinical laboratories across a wide range of therapeutic areas.
Diasorin’s portfolio is structured so that different platforms address distinct workflow and throughput needs.
- LIAISON® XL is a fully automated platform suited for high-throughput hospital and link laboratories, offering a broad CLIA menu and high productivity for routine and specialty testing.
- LIAISON® XS guarantees consistent high-quality diagnostic results but is positioned for small to medium laboratories that need a compact footprint and flexible throughout.
- Simplexa® Direct assays are appropriate when rapid, targeted molecular results are required with minimal hands-on time, for example in acute respiratory testing.
- LIAISON PLEX® panels are best for labs that need flexiblesyndromic, multiplex testing for respiratory and bloodstream infections
- LIAISON NES® assays are best for urgent respiratory results needed at the point of care.
- NxTAG® panels are best for labs that need syndromic, multiplex testing for respiratory infections
- Luminex xMAP® platforms (MAGPIX®, Luminex® 200™, and FLEXMAP 3D® systems) serve mid- to high-plex multiplexing needs in clinical and translational settings. While, the xMAP INTELLIFLEX® (RUO) and MAGPIX (RUO) systems provide mid- to high-plex multiplexing needs in research settings.
When choosing between platforms, laboratories should consider:
- test volume
- menu requirements
- turnaround-time expectations
- available staffing.
Diasorin materials and product specialists can help design configurations that align each lab’s workflow.
Diasorin offers several solutions that support respiratory syndromic testing.
LIAISON PLEX® Respiratory Flex Assay offers customizable syndromic testing, allowing labs to report only what’s necessary, and expand results without retesting based on seasonality and patient need.
Simplexa®COVID-19 / Flu A/B & RSV Direct and other Simplexa® respiratory assays provide rapid molecular detection of key seasonal respiratory viruses directly from clinical specimens.
LIAISON NES® offers two assays: one for simultaneous detection of COVID, Flu A/B and RSV and one for the precise detection of group A strep, aimed at rapid testing in near-patient settings.
NxTAG® Respiratory Pathogen Panel (RPP) v2 and NxTAG® RPP + SARS-CoV-2 broaden coverage to multiple respiratory viruses and bacteria—including influenza A/B, RSV and SARS-CoV-2—in a single syndromic panel.
Together, these solutions allow labs to tailor respiratory testing from high-throughput panels to rapid targeted assays.
xMAP® Technology from Luminex (part of Diasorin) is a bead-based multiplexing platform that allows simultaneous detection of multiple analytes in a single reaction.
Microparticles with distinct signatures are coated with capture molecules, enabling high-plex detection of nucleic acids or proteins on instruments such as MAGPIX® System, Luminex® 200™ System, xMAP INTELLIFLEX RUO Systems, and FLEXMAP 3D® System.
This technology allows clinical and research laboratories to:
- run large panels of targets in a single well
- conserve sample volume
- increase throughput compared with single-plex assays.
xMAP® solutions are used across infectious diseases, immunology, research, and other specialty applications where multiplex information adds clinical value.
NxTAG® assays are used for syndromic panel testing, where multiple pathogens are detected from a single sample.
- The NxTAG® Respiratory Pathogen Panel (RPP) v2 combines multiple viral and bacterial respiratory targets in one assay, enabling laboratories to evaluate a broad set of pathogens when patients present with respiratory symptoms.
This syndromic solution help clinicians interpret complex respiratory clinical presentations more efficiently.
Simplexa® Directassays are real-time PCR tests designed to deliver rapid, sample-to-answer results with streamlined workflows.
Simplexa® Direct assays such as Simplexa® COVID-19 / Flu A/B & RSV Direct allow laboratories to test directly from clinical specimens in a sample format without a separate nucleic-acid extraction step.
This “direct” approach reduces hands-on time and enables faster turnaround for critical infectious-disease targets, supporting rapid decision-making in hospital and lab settings. The expansive and highly differentiated menu includes claims exclusive to Diasorin.
The LIAISON® platform is Diasorin’s family of fully automated chemiluminescent immunoassay (CLIA) analyzers designed for medium- to high-throughput clinical laboratories.
The LIAISON® XL and LIAISON® XS share the same CLIA technology, allowing labs to scale capacity while maintaining consistent results.
LIAISON® systems support a broad range of clinical applications, including:
- Metabolic disorders and Vitamin D testing (e.g., LIAISON® Vitamin D Diagnostic Solution).
- Infectious diseases, with assays such as LIAISON® QuantiFERON® TB-Gold PlusII and a wide menu of viral and bacterial tests.
- Gastrointestinal diseases, including the LIAISON® Calprotectin assay for inflammatory bowel disease (IBD).
- Hepatitis, HIV, and other viral serology including the LIAISON® XL Murex HIV Ab/Ag HT and a full hepatitis menu.
You can use the LIAISON® Family Menu and specialty pages on the website to explore the full test offering.
Diasorin offers a portfolio of platforms that cover immunodiagnostics and molecular diagnostics for clinical laboratories.
The LIAISON® family of analyzers (LIAISON® XL and LIAISON® XS) provides fully automated CLIA immunoassay testing across specialties such as infectious diseases, gastrointestinal diseases, and metabolic disorders.
In molecular diagnostics, Diasorin provides LIAISON NES® for point-of-care,Simplexa® Direct for specialty targeted tests, as well as LIAISON PLEX® and NxTAG® assays for panel-based syndromic testing.
Diasorin provides a full range of diagnostic kits and reagents including:
- CLIA immunoassays for infectious diseases, endocrinology, metabolism and gastrointestinal disorders (LIAISON® XL and LIAISON® XS).
- Targeted PCR-based assays such as Simplexa® C. auris Direct and other targeted infectious disease assays as well as Primer Pairs (ASRs)
- Syndromic multiplex panels through LIAISON PLEX® and NxTAG® technologies (Respiratory, GI, Bloodstream).
- Point-of-care assays on the LIAISON NES® system (Respiratory)
These products are listed across the assay pages in each product family on the US Diasorin website.
You might find this interesting
Immunodiagnostics
Find out moreMolecular Diagnostics
Find out moreTechnical Documentation and Operational Support
Access IFUs, manuals, and essential technical resources.
Find official instructions for use, reagent documentation, maintenance procedures, and operational support materials for Diasorin platforms.
Please contact your Diasorin commercial representative to get a quote on what is required to set up your system and products. They will work with you to provide the best solution for your situation. Diasorin Technical Support can get you to the right person if you need your commercial representative.
Diasorin and Luminex instruments can integrate with numerous vendors for LIS and middleware.
LIAISON® XL automatically adapts to requests for new sample testing, easily pairs with most existing laboratory automation tracks, and guarantees consistent high-quality diagnostic results – ensuring top performance while eliminating bottlenecks in your lab. Please contact your commercial representative for more information.
Discover more about Liasion XL®
On the INTELLIFLEX automation module and device driver enable communication between the reader and a front-end automation platform.
Luminex beads can solve a variety of issues for the market and users. Please reference some links below to learn the importance of Luminex beads.
Bead-Based Multiplexing
Research publications show the importance of the technology.
Research Publications
To learn about bead coupling, please download xMAP® Cookbook.
xMAP® Cookbook
Because each product may have specific storage requirements, the IFU and label are always the reference source.
To store Diasorin reagents correctly, you should:
- Follow exactly the temperature range printed on the label (e.g. 2–8 °C or 15–30 °C, depending on the product).
- Keep reagents in their original bottles or packaging, unopened until use.
- Do not freeze reagents or cassettes unless explicitly allowed in the IFU.
- Do not use reagents beyond their expiration date.
For any doubt, consult the IFU, SDS or your local Diasorin representative.
Each Diasorin and Luminex instrument has user maintenance and some instrument require service maintenance. Please reference the instrument User Manual for information on maintenance requirements or contact Technical Support with questions.
Diasorin and Luminex products require different calibration criteria and quality control criteria. Please refer to the assay IFU for information on how the calibration is performed. Many of Diasorin assays have internal controls available and are compatible with 3rd party controls; reference the product IFU’s for more details.
The complete LIAISON® and Luminex test menus can be accessed in the Immunodiagnostics and Luminex areas of the US Diasorin website.
The LIAISON® section includes dedicated pages for LIAISON® XL, LIAISON® XS, and the LIAISON® Family Menu, which lists all available US assays.
The Luminex section provides an overview of xMAP® assays, instruments, and multiplex capabilities, along with menu details where applicable.
Visit the Immunodiagnostics section
Visit the Luminex section
IFUs for Diasorin and Luminex tests can be accessed through
- Dialog the online platform dedicated to Diasorin customers (regarding Immunodiagnostics and Molecular Diagnostics Solutions)
Access to Dialog - The page Product Documentation (regarding Licensed technologies and Luminex).
Access to Product Documentation
If a specific IFU is not publicly listed, US Diasorin offices can provide the required documentation upon request.
You might find this interesting
Immunodiagnostics and Molecular Diagnostics Instructions for Use
Find out moreLuminex Instructions for Use
Find out moreService & Support
Find out moreCareers
Explore global and local opportunities at Diasorin.
Discover open positions, career development paths, and opportunities across Diasorin’s global teams.
The US website highlights a company culture built around innovation in diagnostics, scientific excellence, and patient-focused impact.
The hiring process typically includes:
- online application through the Careers site
- screening by the recruitment team
- job-specific interviews
- role-related assessments where applicable.
Typical roles in molecular and immunodiagnostics include positions in assay development, clinical affairs, quality assurance, regulatory affairs, manufacturing, field service, and technical support.
You can apply directly through the Join Us section under Careers on the US website, where all active job listings are posted.
Each position includes a detailed description, and an online application form that allows candidates to submit their resume and complete required information.
You can explore job opportunities by filtering or searching within the portal and then follow the application instructions provided in each job posting directly on jobs.Diasorin.com.
Applications are handled through Diasorin’s official recruitment system.
The Careers section also explains Diasorin’s people strategy and how talent and scientific expertise are central to the company’s mission, providing context for these technical roles.
Diasorin offers a wide range of career opportunities across its US sites and global locations, typically including positions in R&D, Quality and Regulatory, Manufacturing, Technical Service, Commercial Operations, and Corporate Functions.
You can find all open job positions at Diasorin in the Join Us section of the Careers area on the US website.
From the main navigation, go to Careers → Join Us, where you are redirected to the Diasorin job portal and explore open positions and opportunities worldwide.
Global opportunities across Europe, the Americas, and APAC are also accessible through the same portal, depending on availability.
You might find this interesting
Contacts
Connect with Diasorin worldwide.
Find contacts, global office locations, and support channels to reach Diasorin teams across regions.
You can find Diasorin's regional contact details in the Diasorin Worldwide section of the website (Company → Diasorin Worldwide).
There you can select your country or region and view the addresses and contact details of local commercial offices, manufacturing sites, and other Group companies.
Regional contacts for the USA distributors are available through the Diasorin Worldwide section under Company.
From this page, you can:
- Select your region and country
- View the local Diasorin company or branch or distributor
- Access addresses and contact information for commercial offices and other entities.
Visit the Diaorin Worldwide section
For additional inquiries - sales inquiries, demo requests, or product information - you can also use the Contact us form and select your country and area of interest (Immunodiagnostics, Molecular Diagnostics, Luminex).
Local technical support and customer service for Diasorin solutions are managed through the Service & Support and Diasorin Worldwide sections of the website.
You can:
- Go to Service & Support and choose Immunodiagnostics, Molecular Diagnostics, or Luminex to access help pages, training sessions, and tools to manage and track orders or service requests
Visit the Service and support section - Use Diasorin Worldwide (Company → Diasorin Worldwide) to identify your local Diasorin office and its contact details.
Visit the Diasorin Worldwide section
If needed, use the Contact us form, selecting your area of interest and country, to request technical assistance or customer support.
Diasorin operates globally with headquarters in Saluggia, Italy, and key business locations across the United States, Europe, and Asia-Pacific.
The US corporate location is in Stillwater, Minnesota, where part of Diasorin’s operations and commercial activities are based.
To see Diasorin’s main offices and local contacts, you can use the Diasorin Worldwide section of the website (Company → Diasorin Worldwide).
There you can select your country or region and view the addresses and contact details of local commercial offices, manufacturing sites, and other Group companies.
Visit the Diasorin Worldwide section
For detailed site information, contact Diasorin directly through the US Contact us form on the Diasorin website, selecting the most relevant reason (e.g. Products info, Sales Inquiry, Business Development).